Cargando…

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in gastrointestinal safety are lacking. We examined the differences in gastrointestinal safety between semaglutide and liraglutide. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu, Chen, Mingyu, Liu, Libin, Chen, Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763271/ https://www.ncbi.nlm.nih.gov/pubmed/35046686 http://dx.doi.org/10.2147/DMSO.S348025

Ejemplares similares

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro
por: Wang, Linxi, et al.
Publicado: (2023)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

A potentially serious adverse effect of GLP-1 receptor agonists
por: Lu, Jinmiao, et al.
Publicado: (2023)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis
por: Chen, Congqin, et al.
Publicado: (2023)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes
por: Palanca, Ana, et al.
Publicado: (2023)

Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
por: Sikirica, Mirko V, et al.
Publicado: (2017)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
por: Vemula, Hasitha, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
por: Amouyal, Chloé, et al.
Publicado: (2016)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data
por: Ahmad, Javaria, et al.
Publicado: (2022)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vciu1vlg8r5l912b6m011lhb5v